11/13/2024 By Brad Sorensen, CFA OTC:BSEM READ THE FULL BSEM RESEARCH REPORT BioStem Technologies, Inc. (OTC:BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the…
The pricing announcement from the Center for Medicare Services became effective on October 1, 2024, and allows BioStem to begin marketing initiatives with Venture Medical POMPANO BEACH, Fla., Oct. 29,…
Retrospective Study demonstrates clinical efficacy and statistical support for tissue processed via BioREtain to care for treatment-resistant chronic wounds Study published in the peer-reviewed journal, ‘International Wound Journal’ POMPANO BEACH,…
Advanced wound care MedTech company recently reported a record second-quarter with $116.4M in revenue for H1, 2024 POMPANO BEACH, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC:…
POMPANO BEACH, Fla., Nov. 08, 2023 — BioStem Technologies Inc. (OTC:BSEM), a leading regenerative medicine company focused on the development, manufacture and commercialization of placental-derived biologics for advanced wound care, today…
POMPANO BEACH, Fla., May 29, 2024 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics, will…
– Company Achieves Record-Breaking First Quarter Results for 2024, Marking the Launch of BioStem 2.0 –– Company Reports First Quarter EBITDA of $4.9 Million –– Project Continued Growth from Sales…
